iCo Therapeutics Oral Amphotericin B Poster at AAPS

    VANCOUVER, Nov. 18 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased
to report that iCo-009, the company's oral Amphotericin B program, has been
accepted for a poster presentation at the American Association of
Pharmaceutical Scientist (AAPS) Meeting in Atlanta, GA.
    The poster, entitled, "Assessing the Antifungal Activity and Renal
Toxicity of Amphotericin B Following the Administration of Novel
Monoglyceride-based Oral Amphotericin B Formulations and Abelcet to Rats
Infected with Aspergillus Fumigatus" (Poster No. T2154), will be presented on
Tuesday, November 18, 2008 from 8am-12pm.
    The poster's authors are Drs. Kishor Wasan, Pavel Gershkovich, Olena
Sivak, Carlos Leon, Ellen Wasan, and Karen Bartlett.

    About iCo-009

    In animal models, oral administration of iCo-009 has been shown to result
in blood levels that are comparable to a known IV Amphotericin B product
currently on the market. In aspergillus fumigatus and candida albicans rat
models, iCo-009 has also shown significant antifungal activity with no
observable kidney toxicity as assessed by plasma creatinine concentrations.
Administration of iCo-009 virtually eradicated a parasitic infection that
causes Visceral Leishmaniasis (VL) in a mouse model of VL. iCo-009 was
developed by Drs. Kishor & Ellen Wasan at the University of British Columbia.
iCo Therapeutics acquired the worldwide exclusive rights to iCo-009 from UBC
in May 2008.

    About iCo Therapeutics

    iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on
redosing or reformulating drugs with clinical history for new or expanded
indications. iCo has exclusive worldwide rights to three products, iCo-007, in
Phase I for the treatment of Diabetic Macular Edema, iCo-008, a product with
Phase II clinical history to be developed for severe ocular allergies, and
iCo-009, an oral reformulation of Amphotericin B for sight and
life-threatening diseases. iCo-009 also represents a new drug delivery
technology with the potential to reprofile other parenterally administered
drugs to the oral route of administration. iCo Therapeutics trades on the
TSX-Venture exchange under the symbol "ICO". For more information, visit the
company website at: www.icotherapeutics.com.

    No regulatory authority has approved or disapproved the content of this
    release. The TSX Venture Exchange does not accept responsibility for the
    adequacy or accuracy of this release.

    Forward Looking Statements

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on iCo
Therapeutics' current beliefs as well as assumptions made by and information
currently available to iCo Therapeutics and relate to, among other things,
anticipated financial performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo Therapeutics in its
public securities filings; actual events may differ materially from current
expectations. iCo Therapeutics disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

    %SEDAR: 00024061E

For further information: Business Development: Dr. John Clement, CBO,
(604) 602-9414 x 222; Finance Contact: Mr. John Meekison, CFO, (604) 602-9414
x 224; Investor, Media Contact: Frederica Bell, Corp. Devt., (604) 602-9414 x
228; B&D Capital, Joanne Calverley, (604) 685-6465